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Abstract Personalized treatment of patients with ad-
vanced non-small-cell lung cancer based on clinical and
molecular tumor features has entered clinical routine prac-
tice. The 2015 pathological classification of lung cancer
mandates immunohistochemical and molecular analysis.
Therapeutic strategies focused on inhibition of angiogen-
esis and growth factor receptor signaling. Inhibitors of
angiogenesis and monoclonal antibodies directed against
the epidermal growth factor receptor have shown efficacy
in combination with chemotherapy. Mutations in the epi-
dermal growth factor receptor and anaplastic lymphoma
kinase have become clinically relevant therapeutic targets.
Immune checkpoint inhibitors are also entering routine
clinical practice. Identification of predictive biomarkers
is essential and faces several challenges including tumor
heterogeneity and dynamic changes of tumor features
over time. Liquid biopsies may overcome some of these
challenges in the future.
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Abbreviations
ALK Anaplastic lymphoma kinase
EGFR Epidermal growth factor receptor
EML4 Echinoderm microtubule-associated protein-like 4
FISH Fluorescence in situ hybridization
IHC Immunohistochemistry
NSCLC Non-small-cell lung cancer
PCR Polymerase chain reaction
SCLC Small-cell lung cancer
TKI(s) Tyrosine kinase inhibitor(s)
1 Introduction
Lung cancer is the most commonly diagnosed cancer worldwide
with 1.82 million cases in 2012 [1]. Pathological classification
into small-cell lung cancer (SCLC) and non-small-cell lung can-
cer (NSCLC) has been standard for assessment of prognosis and
selection of treatment for many years. NSCLC comprises about
80% of all lung cancers.Within the last decade, however, further
subclassification of NSCLC into non-squamous-cell and
squamous-cell NSCLC entered clinical practice. These changes
became necessary after specific anticancer drugs had been shown
to have efficacy or toxicity in certain subtypes of NSCLC [2, 3].
Molecular classification also entered routine practice, mainly
through the identification of molecular therapeutic targets. The
2015 classification of lung cancer now mandates immunohisto-
chemical and molecular analysis in routine clinical practice [4].
Lung cancer is among those cancers with the highest mu-
tation rates [5]. Genome-wide sequencing revealed specific
changes in tumors [6–11]. Among adenocarcinomas, frequent
genetic alterations are mutations in p53, Kirsten rat sarcoma
viral oncogene homolog (KRAS), cyclin-dependent kinase
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inhibitor 2A (CDKN2A), mixed-lineage leukemia 3 (MLL3),
serine/threonine kinase 11 (STK11), and the epidermal
g rowth f ac to r r e cep to r (EGFR ) [6–9 ] . Among
squamous-cell NSCLC, frequent mutations are seen in
phosphatidylinositol-4-5-biphosphate 3-kinase (PIK3CA),
sex-determining region Y-related gene family 2 (SOX2),
CDKN2A, fibroblast growth factor receptor 1 (FGFR1), and
MLL3 [10]. Among small-cell lung cancers, frequent muta-
tions are seen in retinoblastoma 1 (RB1), E1A-binding protein
p300 (EP300), MLL2, and PIK3CA [11].
The identification of specific mutations including driver
mutations in certain histological subtypes has led to molecular
subclassification of NSCLC and also opened therapeutic op-
portunities for personalized medicine (also termed precision
medicine) based on these molecular targets. Driver mutations
involved in tumor growth were of particular therapeutic inter-
est because their blockade opened the possibility for improved
clinical outcome of patients. Driver mutations of current ther-
apeutic relevance for routine practice are those seen in the
epidermal growth factor receptor (EGFR), anaplastic lympho-
ma kinase (ALK), and ROS1. The identification of driver
mutations in squamous-cell carcinomas and small-cell lung
cancer may have therapeutic implications in these carcinomas
in the near future [10]. Immune checkpoint inhibitors have
shown efficacy in phase III trials in patients with advanced
NSCLC who have been pretreated with chemotherapy [12,
13]. Research on predictive biomarkers is currently ongoing.
Here we summarize the current status of personalized treat-
ment based on predictive biomarkers in patients with ad-
vanced NSCLC in routine clinical practice.
2 Tumor histology
Classification of lung cancer into NSCLC and SCLC was
sufficient for management of patients with lung cancer in rou-
tine practice for many years. During the last decade, however,
NSCLC subclassification by means of immunohistochemistry
and molecular factors has become clinically mandatory [4].
Reasons for this are better understanding of tumor biology,
preferential efficacy or toxicity of novel drugs in subtypes of
NSCLC, and the demonstration of therapeutically relevant
driver mutations in subsets of NSCLC.
The interaction between tumor histology and drug efficacy
was observed in case of pemetrexed which was shown to have
preferential efficacy in patients with non-squamous NSCLC.
In a phase III trial in chemo-naïve patients with advanced
NSCLC, cisplatin plus pemetrexed increased overall survival
compared to cisplatin plus gemcitabine in patients with
non-squamous-cell NSCLC [2]. Bevacizumab was mainly de-
veloped in only patients with non-squamous NSCLC because
an early clinical trial suggested increased rates of bleedings in
patients with squamous-cell NSCLC [3]. Based on these
findings, subtyping of NSCLC into non-squamous-cell and
squamous-cell NSCLC entered routine clinical practice.
The subclassification of NSCLC has also become necessary
for guiding molecular analyses because EGFR mutations and
other driver mutations were preferentially detected in patients
with adenocarcinomas. Patients with advanced adenocarci-
nomas are currently tested for EGFR mutations, ALK aberra-
tions, and ROS1 in routine clinical practice. Based on local
practice and possibilities, additional molecular markers are de-
termined. The 2015 classification of lung cancer requires im-
munohistochemical and molecular analyses of tumors [4].
3 Customized chemotherapy
Customized chemotherapy based on molecular tumor features
has extensively been studied and is beyond the present review.
Research has focused on ERCC1, RRM1, and thymidylate syn-
thase as potential biomarkers. ERCC1 was initially shown to
predict outcome of adjuvant chemotherapy [14]. The validation
in the LACE Bio project, however, failed to confirm these find-
ings [15]. Palliative chemotherapy based on ERCC1 levels failed
to demonstrate a survival advantage compared to a standard pro-
tocol [16]. Because no biomarker could reliably predict clinical
outcome of chemotherapy, customized chemotherapy based on
molecular markers has not entered routine clinical practice.
4 EGFR tyrosine kinase inhibitors
Blockade of EGFR by tyrosine kinase inhibitors (TKIs) or
monoclonal antibodies improved outcome in patients with
advanced NSCLC (for review, see [17–19]).
First-generation EGFR TKIs, e.g., gefitinib and erlotinib,
have initially been evaluated in unselected patients with ad-
vanced NSCLC who had progressed during or after palliative
chemotherapy (for review, see [17, 18]). In 2004,
EGFR-activating mutations have been identified in tumors
of those patients who had shown excellent responses to
EGFRTKIs [20–22]. EGFRmutations in advanced adenocar-
cinomas are detected in approximately 10–15 % of Caucasian
patients and 40–60 % of patients of Southeast Asian ethnicity.
The identification of EGFR mutations led to phase III trials
comparing EGFR TKIs with palliative chemotherapy in pa-
tients with advanced EGFR mutation-positive NSCLC (for
review, see [17, 18]). EGFR TKIs (afatinib, erlotinib, gefitin-
ib) administered until disease progression prolonged
progression-free survival and improved quality of life in com-
parison to first-line chemotherapy in patients with
EGFR-activating mutations but were inferior to chemotherapy
in patients without these mutations. Afatinib also increased
overall survival compared to chemotherapy, and this survival
benefit was seen in patients with exon 19 deletions [23]. The
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results of these phase III trials led to the approval of EGFR
TKIs for first-line therapy of patients with advanced EGFR
mutation-positive NSCLC and to clinical practice guidelines
recommending, first, EGFR mutation testing for all patients
with advanced adenocarcinomas, and, second, EGFRTKIs as
the preferred first-line therapy for patients with advanced
EGFR mutation-positive NSCLC [24–27]. Recently, afatinib
was also shown to increase survival compared to erlotinib in
patients with advanced squamous-cell NSCLC who had
progressed after pretreatment with chemotherapy [28].
After median progression-free survival times of approxi-
mately 9–13 months, patients with EGFR mutation-positive
NSCLC usually acquire resistance to EGFR TKIs. Acquired
resistance may be pharmacological or caused by molecular
changes of the tumor [29, 30]. Molecular mechanisms of ac-
quired resistance are EGFR target alterations in about 60 %,
non-EGFR bypass track alterations in about 20 % of patients,
histological transformation to small-cell lung cancer, epitheli-
al–mesenchymal transformation, and yet to be identified
mechanisms in the remaining patients [29, 30]. EGFR
target alterations are mainly T790M mutations within exon
20 which occur alone in 40–55 % and in combination with
EGFR amplification in 10 % of the patients. The T790M
mutation leads to an enhanced affinity for adenosine triphos-
phate, thereby reducing the ability of reversible EGFRTKIs to
bind to the tyrosine kinase domain of EGFR. Treatment op-
tions at the time of acquired resistance are continuation of
treatment with TKIs in selected patients with clinically slow
progression, addition of local radiotherapy, and switch to ei-
ther chemotherapy or third-generation EGFR TKIs.
Cetuximab combined with either afatinib or chemotherapy
has also been studied [31, 32].
Third-generation TKIs are active against EGFR-activating
mutations and the T790M resistance mutation and have only
limited efficacy against wild-type EGFR. Drugs in clinical
development include osimertinib, rociletinib, and HM61713
[33–37]. Osimertinib and rociletinib have shown clinical effi-
cacy in phase I/II trials in patients with acquired resistance to
first-generation or second-generation TKIs and are currently
compared to standard treatment in phase III trials in patients
with advanced EGFR mutation-positive NSCLC [35, 36].
Patients undergoing treatment with third-generation EGFR
TKIs will eventually also develop resistance through the
emergence of one of the following three resistance mutations:
EGFR L718Q, L844V, and C797S [38, 39].
4.1 EGFR mutations as predictive biomarkers
EGFR TKIs were found to be preferentially active in patients
with adenocarcinomas, never-smokers, and patients of
Southeast Asian ethnicity. In 2004, EGFR activating muta-
tions have been identified in patients with good responses to
TKIs [20–22]. Phase III trials then demonstrated superior
outcome of TKIs compared to first-line chemotherapy in pa-
tients with advanced EGFR mutation-positive NSCLC (for
review, see [17, 18]). These results led to the approval of
EGFR TKIs for first-line therapy in patients with advanced
EGFR mutation-positive NSCLC. These approvals then re-
quired the implementation of EGFR mutation testing in rou-
tine clinical practice for patients with adenocarcinomas.
EGFRmutation testing has now been established in routine
clinical practice in most cancer centers of the world. In this
context, close co-operation and communication between
treating physicians and pathologists have been important.
Educational meetings also facilitated the widespread imple-
mentation of testing.
The Implementation of Personalized Medicine in NSCLC
in Central Europe: EGFR Testing, Histopathology, and
Clinical Features (INSIGHT) observational study confirmed
that EGFR mutation testing has been implemented in routine
clinical practice and that patients with advanced EGFR
mutation-positive NSCLC preferentially receive EGFR TKIs
as first-line therapy [40]. This study in the real-world setting
enrolled 1785 patients from 14 cancer centers of six Central
European countries where lung cancer incidence rates are par-
ticularly high. Primary tumors were the most common sample
source for mutation testing. This reflects the fact that tumor
specimens were obtained by bronchoscopy or CT-guided bi-
opsy in the majority of patients. EGFR mutation testing was
done by one of the standard tests available in the respective
countries. These tests included polymerase chain reaction
(PCR)-RFLP, Sanger sequencing, Roche Cobas EGFR muta-
tion test, or other methods. EGFR mutations were detected in
tumors of 13.8 % of the patients. The mutation rates for his-
tological and cytological specimens were 14.6 and 12.9 %,
respectively. Exon 19 deletions were seen in 43.3 % and
L858R point mutations in 28.3 % of the mutation-positive
patients, respectively. T790M mutations and exon 20 inser-
tions were seen in 1.2 and 3.6 % of the patients, respectively.
Positive mutation rates varied from 10.8 to 26.7 % between
centers, and this variation probably reflects differences in pa-
tient selection for EGFR mutation testing. The mutation rates
were 5.7, 12.1, and 40.4 % in smokers, former smokers, and
never-smokers, respectively. Data on first-line systemic ther-
apy were available for 184 patients with advanced EGFR
mutation-positive NSCLC. In 82.6 % of the patients, the mu-
tation status was available before initiation of first-line thera-
py, and the majority of these patients were treated with EGFR
TKIs. None of the patients without documented EGFR muta-
tions received first-line therapy with an EGFR TKI.
The recent findings on the efficacy of third-generation
EGFR TKIs in patients with T790M-positive disease require
the proof of the presence of this resistance mutation in tumors
at the time of disease progression in routine clinical practice.
In one study on 93 patients with acquired resistance to EGFR
TKI, 62 % of them had T790M mutations in their tumors at
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the time of re-biopsy [29]. Patients with T790Mmutations had
a more favorable prognosis compared to T790M-negative pa-
tients. T790M was more common in biopsies of lung/pleura
tissue and lymph nodes than in more distant sites. Patients
without T790M were found to more often progress in previ-
ously uninvolved organs.
Although EGFR mutation testing at the time of diagnosis
has been established, several challenges remain. These in-
clude insufficient tumor tissues, intratumoral heterogeneity,
heterogeneity between primary and metastatic tumors, and
re-biopsy at the time of disease progression. Heterogeneity
between primary tumors and lymph node metastases does
occur and requires further studies in the future [41]. Several
of the challenges may be overcome by liquid biopsies in the
future (see below).
5 EGFR monoclonal antibodies
Several anti-EGFR monoclonal antibodies have been evaluat-
ed in clinical trials (for review, see [19]). First-line chemother-
apy combined with cetuximab improved outcome including
overall survival in patients with advanced NSCLC [42, 43].
This benefit of cetuximab was seen in the FLEX trial, in which
an enrichment strategy for EGFR expression was used for
patient inclusion, and was confirmed in a meta-analysis based
on 2018 patients from four randomized trials including the
BMS099 trial [42, 43]. In the BMS099 trial, no significant
benefit was seen when cetuximab was added to carboplatin
plus paclitaxel in unselected patients [44].
Necitumumab added to first-line chemotherapy increased
survival of patients with advanced squamous-cell NSCLC in
the SQUIRE trial [45]. The SQUIRE trial randomized patients
to chemotherapy plus cetuximab or chemotherapy alone.
Chemotherapy consisted of cisplatin plus gemcitabine. The
trial demonstrated increased overall survival and
progression-free survival for the combined treatment. With
regard to survival, the hazard ratio was 0.84 (0.74–0.96). In
contrast to the SQUIRE trial, the INSPIRE trial failed to dem-
onstrate a benefit for necitumumab added to cisplatin plus
pemetrexed compared to chemotherapy alone in patients with
advanced non-squamous-cell NSCLC [46].
5.1 Predictive biomarkers
The results with regard to biomarker analysis for cetuximab
and necitumumab are summarized in Table 1. Based on the
results from the meta-analysis, the survival benefit of
cetuximab was greatest in patients with squamous-cell carci-
nomas with a hazard ratio of 0.77 (95 % confidence interval
Table 1 EGFR monoclonal antibodies and biomarkers in advanced NSCLC
Overall survival hazard ratio (95 % CI) P References
Cetuximab
FLEX ITT All 0.87 (0.76–0.99) 0.04 [42, 47]
High H score 0.73 (0.58–0.93)
Squamous All 0.80 (0.64–1.00)
High H score 0.62 (0.43–0.88)
Adeno All 0.94 (0.77–1.15)
High H score 0.74 (0.48–1.14)
BMS099 ITT 0.89 (0.75–1.05) NS [44]




SWOG S0819 ITT All 0.94 (0.84–1.06) NS [50]
FISH-positive 0.83 (0.67–1.04) 0.1
Squamous All 0.85 (0.67–1.08) 0.18
FISH-positive 0.56 (0.37–0.84) 0.006
Necitumumab
SQUIRE Squamous All 0.84 (0.74–0.96) 0.01 [45, 48]
High H score 0.75 (0.60–0.94)
FISH-positive 0.70 (0.52–0.96)
INSPIRE Adeno All 1.01 (0.84–1.21) NS [46]
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(CI) 0.64–0.93) [43]. Necitumumab improved survival in
squamous-cell NSCLC but not in non-squamous-cell
NSCLC [45, 46].
High EGFR expression based on an immunohistochemis-
try score was shown to predict survival benefit from the addi-
tion of cetuximab to chemotherapy in the FLEX trial, whereas
patients with low expression did not benefit [47]. The interac-
tion test between EGFR expression levels of tumors and ben-
efit from combined treatment was significant [47]. The
greatest survival benefit of cetuximab with a hazard ratio of
0.62 (95 % CI 0.43–0.88) was seen in patients with
squamous-cell NSCLC and high EGFR expression [47].
Similarly, high EGFR expression was associated with a great-
er survival benefit (hazard ratio 0.75, 95 % CI 0.60–0.94)
from the addition of necitumumab to chemotherapy in the
SQUIRE trial which enrolled only patients with
squamous-cell NSCLC [48].
EGFR fluorescence in situ hybridization (FISH) positivity
suggested benefit from cetuximab when added to first-line
chemotherapy in a phase II trial [49] and led to the SWOG
S0819 phase III biomarker validation study [50]. Patients
were randomized into chemotherapy plus cetuximab or che-
motherapy alone. Chemotherapy consisted of cisplatin plus
paclitaxel with or without bevacizumab. Cetuximab did not
improve outcome in the total study population. In patients
with FISH-positive tumors, however, the hazard ratio for sur-
vival was 0.83 (95 % CI 0.67–1.04) in favor of chemotherapy
plus cetuximab compared to chemotherapy alone. This differ-
ence was even greater in patients with squamous-cell NSCLC
in whom the hazard ratio was 0.56 (0.37–0.84) for patients
with FISH-positive tumors.
The benefit from necitumumab added to cisplatin plus
gemcitabine in patients with squamous-cell NSCLC appeared
to be greater in patients with high EGFR expression levels or
those with FISH-positive tumors [48]. With regard to both pa-
rameters, however, the interaction between marker levels and
clinical outcome did not reach statistical significance.
Markers other than EGFR immunohistochemistry or FISH
were also evaluated as potential predictive biomarkers. KRAS
mutations had no predictive value with regard to cetuximab
[51, 52]. Early onset skin rash was associated with better prog-
nosis of patients treated with chemotherapy plus cetuximab,
although a predictive role could not be proven [53].
Taken together, both high EGFR expression and FISH pos-
itivity of tumors did predict benefit from EGFR-directed
monoclonal antibodies when added to first-line chemotherapy
of patients with advanced NSCLC.
6 ALK
Echinoderm microtubule-associated protein-like 4
(EML4)-ALK fusion proteins were recently detected in 3–
5 % of NSCLC, particularly in adenocarcinomas. Patients
with ALK-positive tumors do benefit from treatment with
crizotinib compared to chemotherapy in terms of
progression-free survival and quality of life, as demonstrated
for both patients pretreated with chemotherapy and chemo-
naïve patients [54, 55]. Second-generation ALK inhibitors
are also in development [56]. Therefore, assessment of ALK
status has become diagnostic standard in routine practice for
patients with advanced adenocarcinomas of the lung. Most
recently, patients with ROS1-positive tumors were also shown
to benefit from treatment with crizotinib [57].
6.1 Predictive biomarkers
Techniques for assessing the ALK status are real-time
RT-PCR, FISH, and direct sequencing. FISH break-apart
probe remains the gold standard in the detection of ALK re-
arrangement in tissues. In several countries, ALK immunohis-
tochemistry (IHC) is used as a screening test and IHC-positive
cases are then confirmed by FISH.
ROS1 is also routinely assessed, mostly by means of IHC
screening followed by FISH confirmation of those with positive
IHC.
7 Angiogenesis inhibitors
Angiogenesis inhibitors have extensively been studied in pa-
tients with advancedNSCLC. Bevacizumab added to first-line
chemotherapy improved clinical outcome in patients with ad-
vanced non-squamous-cell NSCLC and has been approved
for these patients [58, 59]. Nintedanib, a triple kinase inhibi-
tors, has been studied in combination with second-line che-
motherapy in patients with advanced NSCLC in the LUME
Lung 1 and 2 trials. In both trials, progression-free survival
was prolonged with chemotherapy plus nintedanib compared
to chemotherapy alone. Nintedanib added to docetaxel also
increased overall survival compared to docetaxel alone in pa-
tients with adenocarcinomas [60]. In the European Union,
nintedanib has been approved in combination with docetaxel
for patients with advanced adenoarcinomas who have been
pretreated with chemotherapy.
7.1 Predictive biomarkers
Translational research has focused on the characterization of
predictive biomarkers for angiogenesis inhibitors. In case of
bevacizumab, however, no predictive biomarker has yet been
characterized for use in routine clinical practice.
In the LUME Lung 1 trial, overall survival was statistically
analyzed according to a hierarchical approach under consid-
eration of findings from the LUME Lung 2 trial which sug-
gested benefit of nintedanib for patients who progressed
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within 9 months from time of initial diagnosis [60]. First,
patients with adenocarcinomas and progression within
9 months from the time of initial diagnosis were analyzed.
After demonstrating the benefit of combined treatment in
these patients, patients with adenocarcinomas were analyzed
and found to have a survival benefit from combined treatment.
Finally, analysis of the total study population failed to show a
significant survival benefit in these patients. These findings,
first, led to the approval of nintedanib in combination with
docetaxel in patients with adenocarcinomas who have been
pretreated with chemotherapy and, second, also supported
the predictive value of early progression.
8 Immune checkpoint inhibitors
Immune checkpoint inhibitors have opened new therapeutic
options in patients with advanced NSCLC. These drugs are
directed against cytotoxic T lymphocyte-associated antigen 4
(CTLC4), programmed death-1 (PD-1), and PD-1 ligands
PD-L1 and PD-L2. Drugs already studied or in development
in lung cancer are ipilimumab, nivolumab, pembrolizumab,
atezolizumab, durvalumab, and avelumab. Nivolumab and
pembrolizumab have shown efficacy in phase III trials in pa-
tients with advanced NSCLC who had been pretreated with at
least one line of chemotherapy [12, 13]. Response rates ranged
around 20 %, and the survival gain at 1 year compared to
docetaxel was about 20 % in unselected patients.
8.1 Predictive biomarkers
Research has focused on the characterization of those patients
who derive the benefit from immune checkpoint inhibitors.
Over-expression of PD-L1 or PD-L2 on tumor cells has been
explored as a potential predictive biomarker. In case of
nivolumab, high expression of PD-L1 was associated with
greater benefit from nivolumab in patients with non-
squamous-cell NSCLC, whereas no such difference in outcome
was shown for patients with squamous-cell NSCLC [13, 14]. In
the atezolizumab randomized phase II trial in pretreated patients
with advanced NSCLC, PD-L1 expression was evaluated by
immunohistochemistry by means of the SP142 antibody on tu-
mor samples and tumor-infiltrating immune cells [61]. The
greatest improvement appeared to occur in patients with the
highest PD-L1 levels on tumor cells or on immune cells.
Other studies evaluated tumor-infiltrating immune cells,
interferon-gamma, and other factors of the tumor microenvi-
ronment. Gene analyses focusing on mutation loads and mis-
match repair deficiency are also promising. NSCLC and mel-
anomas, for which immune checkpoint inhibitors are already
in clinical use, have the highest mutation rates among all ma-
lignant diseases [5]. These mutations result in high levels of
mutated proteins which will then serve as tumor antigens and
may make these cancers susceptible for immunotherapy.
Standardization of testing remains a major challenge for the
clinical development of predictive biomarkers. Differences in
type of markers, test methods, and cutoff levels between trials
make comparisons of results between trials very difficult.
Overall, the identification of predictive biomarkers for im-
mune checkpoint inhibitors is complex. Development of reli-
able predictive biomarkers has to consider tumor heterogene-
ity, differences between primary tumors and metastases, dy-
namic changes of biomarkers over time, test methods, and
other factors. With regard to testing, tumor volume and tumor
cell density are important. Based on this complexity, no pre-
dictive biomarker has yet been characterized for use in routine
clinical practice.
9 Challenges of molecular testing in routine clinical
practice
In order to establish and implement molecular testing in rou-
tine practice, co-operation and communication between the
treating physicians and the pathologists are of particular im-
portance as stressed in the First EuropeanWorkshop on EGFR
mutation testing [25]. The detailed logistics of testing, how-
ever, are best established at the local level because strategies
that work in one cancer center may not necessarily be the most
appropriate ones in others. Although the decision which pa-
tients should be tested is the primary responsibility of the
treating physician, this strategy can be time consuming and
may delay the time when test results will be available for the
clinician. Therefore, many cancer centers have adopted a re-
flex testing strategy where the pathologists forward the tumor
samples for molecular analysis as soon as they have
established the histological diagnosis. This strategy is more
efficient and allows test results to become available for the
treating physician within clinically acceptable time periods.
9.1 Tumor specimens
Tumor specimens obtained at the time of initial diagnosis are
also used for molecular testing in routine clinical practice. The
selection of the tumor site for biopsy depends on its accessibility
and must consider being associated with the lowest risk and
burden for the patient. Modern biopsy techniques often provide
only small tumor specimens, and this may impact on molecular
analysis because histological confirmation of cancer remains the
most important goal of tumor biopsies. Only after the diagnosis
has clearly been established, the remaining tissue can then be
used for molecular analysis. This strategy may result in insuffi-
cient tumor tissue for molecular analysis and may require
re-biopsy, dependent on the clinical situation. Therefore,
methods for tumor sampling need improvement in order to
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provide tissue that will be sufficient for both histological and
molecular diagnosis. In the future, liquid biopsies will become
an important additional source for molecular analysis.
Source, handling, and fixation of tumor specimens have to be
standardized. Pathologists should provide physicians who will
perform the biopsy with a standardized protocol on sampling
and handling of tumors. Based on the INSIGHT study, tumor
samples were obtained by bronchoscopy, EBUS/EUS, and
computer-tomography-guided biopsy or surgery [40]. Primary
tumors, lymph nodes metastases, and distant metastases were
used for pathological and molecular diagnosis in 85.7, 2.6, and
11.7 % of the patients, respectively. Pathological diagnosis was
based on histology (with or without cytology) in 82.2 % and on
cytology alone in 17.8 % of the patients.
9.2 Re-biopsies
Molecular analysis is increasingly becoming important also at
the time of tumor progression. As an example, the clinical pre-
scription of third-generation EGFR TKIs requires the proof of
the presence of the T790M resistance mutation in tumor cells.
With regard to the site of re-biopsy, the most easily accessible
tumor site should be selected in routine clinical practice.
Re-biopsy at the time of tumor progression can be particularly
challenging because patients may have poor performance status,
may suffer from heavy symptom load, or may refuse re-biopsy.
Therefore, non-invasive approaches such as liquid biopsies may
become promising sources for tumor genotyping.
9.3 Liquid biopsies
The procedure of taking blood samples to detect
tumor-specific genetic alterations is termed Bliquid biopsy.^
Liquid biopsies are currently studied as a potential alternative
source for molecular analyses. Tumor materials obtained from
the peripheral blood include circulating cell-free DNA
(cfDNA), circulating tumor cells (CTCs), and exosomes.
cfDNA is composed of small fragments of nucleic acids that
are not associated with cells or cell fragments, whereas circu-
lating tumor cells represent intact, viable cells that can be
purified from blood. Exosomes are extracellular vesicles that
contain RNA, DNA fragments, proteins, and metabolites.
Blood samples can easily and repeatedly be taken and may
also allow detecting genetic heterogeneity of tumors.
Blood-based analytic approaches may allow real-time moni-
toring of the total tumor burden and the detection of mutations
during treatment.
9.3.1 Circulating cell-free DNA
Circulating cell-free DNA (cfDNA) consists of DNA frag-
ments which originate from tumor cells but also normal cells
that are released into the bloodstream. Although cancer
patients tend to have higher levels of cfDNA, the levels of
tumor-derived, circulating cfDNA are usually low.
Therefore, the discrimination of mutated cfDNA from
wild-type cfDNA requires high sensitivity of the test methods.
The following methods for the analysis of tumor-derived
cfDNA are available: digital polymerase chain reaction
(PCR); beads, emulsion, amplification, and magnetics
(BEAMing); pyrophosphorolysis-activated polymerization
(PAP); and tagged-amplicon deep sequencing (TAM-Seq).
The sensitivity of these techniques is limited due to low num-
ber of tumor-derived cfDNA copies and error rates of the
polymerases used for PCR. Digital platforms are more sensi-
tive than non-digital platforms as recently demonstrated for
the detection of EGFR mutations in circulating cfDNA of
patients with advanced NSCLC [62].
Liquid biopsies were used to detect and monitor mutations
[39, 62–65]. In a recent study, next-generation sequencing of
cell-free plasma DNA (cfDNA) from patients with advanced
lung cancer whose tumors had developed resistance to
osimertinib revealed an acquired EGFR C797S mutation [39].
Another study demonstrated the feasibility of detecting
and monitoring of EGFR mutations in cell-free plasma
DNA from patients with EGFR-mutated advanced
NSCLC undergoing treatment with erlotinib [64]. Serial
quantifications of cell-free plasma DNA demonstrated that
the T790M mutation could be detected several weeks be-
fore radiographic progression.
In an exploratory study of 40 patients with EGFR
mutation-positive tumors progressing on EGFR TKI therapy,
the T790M genotype from tumor biopsies was compared with
findings from simultaneously collected circulating tumor cells
and circulating tumor DNA [65]. T790M genotypes were suc-
cessfully obtained in 75 % of the tumor biopsies, 70 % of the
circulating tumor cell samples, and 80 % of circulating tumor
DNA samples. T790M was detected in 47–50 % of patients
with a concordance rate of 57–74 %. Circulating tumor cell–
based and circulating tumor DNA–based genotyping were
each unsuccessful in 20–30 %. The combination of both tests,
however, allowed successful genotyping in all patients.
T790M mutations were detected in 35 % of the patients in
whom tumor biopsy was negative or indeterminate.
Therefore, tumor biopsy and blood-based analyses may give
discordant results, but the use of complementary approaches
may provide more relevant results.
Liquid biopsies will contribute to a deeper insight in
the molecular development of resistance mechanisms and
will enable continuous monitoring of the tumor genotype
including the detection of molecular relapses prior to ra-
diographic or clinical progression. The results of liquid
biopsies will have to be compared with those from tumor
biopsies and will have to be shown that they allow clini-
cally reliable treatment guidance. Therefore, further re-
search is necessary before liquid biopsies can be
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recommended as a routine method for guiding treatment
of patients with molecular alterations in their tumors.
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